Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TARS Tarsus Pharmaceuticals, Inc.

Closed 09-18 16:00:00 EDT

78.09

-0.94

-1.19%

盘后78.09

+0.000.00%

19:30 EDT

High79.10	Low77.33	Vol710.97K
Open78.67	D1 Closing79.03	Amplitude2.24%
Mkt Cap3.43B	Tradable Cap2.78B	Total Shares43.88M
T/O55.55M	T/O Rate1.99%	Tradable Shares35.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":78.09,"timestamp":1789761600000,"preClose":79.03,"halted":0,"volume":710968,"hourTrading":{"tag":"盘后","latestPrice":78.09,"preClose":78.09,"latestTime":"19:30 EDT","volume":73824,"amount":5764921.7639,"timestamp":1789774206868,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011894217385802831,"floatShares":35638300,"shares":43882996,"eps":-1.082408,"marketStatus":"Closed","change":-0.94,"latestTime":"09-18 16:00:00 EDT","open":78.67,"high":79.1,"low":77.33,"amount":55550567.531279996,"amplitude":0.022397,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.082408,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":79.03,"preHourTrading":{"tag":"盘前","latestPrice":78.7,"preClose":79.03,"latestTime":"09:29 EDT","volume":53,"amount":4215.440329999999,"timestamp":1789738193102,"change":-0.33,"changeRate":-0.004176,"amplitude":0.019069},"postHourTrading":{"tag":"盘后","latestPrice":78.09,"preClose":78.09,"latestTime":"19:30 EDT","volume":73824,"amount":5764921.7639,"timestamp":1789774206868,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.208251,"impliedVol":0.8021,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/TARS/tweets","defaultTab":"tweets","newsList":[{"id":"2668992592","title":"Tarsus Director William J. Link Reports Disposal of Common Shares Worth $977,707.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992592","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668992592?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:23","pubTimestamp":1789676614,"startTime":"0","endTime":"0","summary":"Tarsus director William J. Link reports disposal of common shares worth $977,707.22Director William J. Link PhD sold 12,500 Tarsus Pharmaceuticals common shares on Sep. 15, 2026 at prices near USD 78-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL1FPtlZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tarsus Director William J. Link Reports Disposal of Common Shares Worth $977,707.22","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667705985","title":"Tarsus Pharmaceuticals Price Target Announced at $110.00/Share by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2667705985","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667705985?lang=en_us&edition=fundamental","pubTime":"2026-09-16 21:05","pubTimestamp":1789563900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667947602","title":"Tarsus Pharmaceuticals, Inc. : Barclays Reinstates Coverage with Overweight Rating; Price Target $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2667947602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667947602?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:22","pubTimestamp":1789554134,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4570QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667865044","title":"Q32 Bio Names José Trevejo Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667865044","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667865044?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:59","pubTimestamp":1789383556,"startTime":"0","endTime":"0","summary":"Q32 Bio names José Trevejo chief medical officerQ32 Bio named José Trevejo as chief medical officer.Trevejo was chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics.Earl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDLbs27vy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","SRNE","BK4139","BK4539","BK4007","TARS","QTTB","IVVD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516850","title":"Tarsus Pharmaceuticals Completes Alkeus Retinal Therapy Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516850","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516850?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:34","pubTimestamp":1789072488,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals ( ($TARS) ) has shared an announcement. On Sept. 4, 2026, Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-completes-alkeus-retinal-therapy-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-completes-alkeus-retinal-therapy-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666700537","title":"Tarsus COO Neervannan Seshadri Sells 4,564 Shares Worth $387,940","url":"https://stock-news.laohu8.com/highlight/detail?id=2666700537","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666700537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:13","pubTimestamp":1788984821,"startTime":"0","endTime":"0","summary":"Tarsus COO Neervannan Seshadri sells 4,564 shares worth $387,940Chief Operating Officer Neervannan Seshadri sold 4,564 Tarsus Pharmaceuticals common shares on Sept. 4, 2026 at USD 85.Directly held sta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3D86F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tarsus COO Neervannan Seshadri Sells 4,564 Shares Worth $387,940","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666310372","title":"Tarsus Pharmaceuticals is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666310372","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666310372?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:00","pubTimestamp":1788894000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374189","title":"Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374189","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374189?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:55","pubTimestamp":1788890123,"startTime":"0","endTime":"0","summary":"Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $105 from $88 and keeps a Buy rating on the shares. The firm notes the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-raised-to-105-from-88-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-price-target-raised-to-105-from-88-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374136","title":"Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374136?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:55","pubTimestamp":1788890117,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dennis Ding from Jefferies reiterated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","TARS","BK4585","BK4007","XBI","BK4588","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332318","title":"Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332318","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664332318?lang=en_us&edition=fundamental","pubTime":"2026-09-04 21:08","pubTimestamp":1788527280,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) said Friday that it has completed its acquisition of retinal disease-focused biotechnology company Alkeus Pharmaceuticals.Tarsus said that with the completion of the acqu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664033453","title":"Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2664033453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664033453?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:38","pubTimestamp":1788525523,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA5NMDWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664801447","title":"Tarsus CMO Elizabeth Yeu Disposes of Common Shares Worth $787,879.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2664801447","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664801447?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:30","pubTimestamp":1788467435,"startTime":"0","endTime":"0","summary":"Tarsus CMO Elizabeth Yeu disposes of common shares worth $787,879.86Tarsus: Chief Medical Officer Lin Elizabeth Yeu sold 9,988 common shares on Sep. 1-2, cutting direct holdings to 13,320.Sale prices ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5TKtFc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tarsus CMO Elizabeth Yeu Disposes of Common Shares Worth $787,879.86","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664503869","title":"Tarsus Pharmaceuticals to Attend Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664503869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664503869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:30","pubTimestamp":1788294617,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals to attend Wells Fargo healthcare conferenceTarsus Pharmaceuticals will attend the Wells Fargo 21st Annual Healthcare Conference on Sept. 8.Management will also attend the H.C. W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL78Wr8t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2V16.EUR","BCDF","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014021.USD","NDAQ","BK4112","LU0314104364.USD","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BQXX3C00.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","TARS","IE00BQXX3F31.USD","LU2210149790.SGD","SG9999014005.SGD","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664694038","title":"Tarsus to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664694038","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664694038?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:30","pubTimestamp":1788294600,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Farg","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354629/0/en/tarsus-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660545237","title":"Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660545237","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660545237?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:21","pubTimestamp":1787030482,"startTime":"0","endTime":"0","summary":"Why Tarsus Pharmaceuticals stock is in focus after Q2 2026\nTarsus Pharmaceuticals (TARS) is back on investors radar after its Q2 2026 earnings report showed higher revenue, a smaller net loss, and a higher full year sales outlook for XDEMVY.\nSee our latest analysis for Tarsus Pharmaceuticals.\nTarsus Pharmaceuticals shares have reacted positively to the Q2 2026 update, with a 17.99% 1 month share price return and a 15.21% 3 month share price return, while the year to date share price is still...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-shares-just-moved-what-is-behind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-shares-just-moved-what-is-behind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658189906","title":"Tarsus Pharmaceuticals Price Target Raised to $100.00/Share from $97.00 by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658189906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658189906?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:26","pubTimestamp":1786548360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658909977","title":"Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658909977","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658909977?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:33","pubTimestamp":1786538039,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $95.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658867210","title":"Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus","url":"https://stock-news.laohu8.com/highlight/detail?id=2658867210","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658867210?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:35","pubTimestamp":1786264551,"startTime":"0","endTime":"0","summary":"In early August 2026, Tarsus Pharmaceuticals reported second-quarter revenue of US$173.91 million and a net loss of US$18.55 million, while also raising full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million.\nThe earnings update highlighted strong XDEMVY uptake, with more than 700,000 patients treated since launch and an acquisition of Alkeus Pharmaceuticals to broaden Tarsus’ ophthalmology pipeline.\nWe’ll now examine how this stronger XDEMVY sales outlook and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-xdemv","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-xdemv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364252","title":"Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364252?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:45","pubTimestamp":1786113957,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $94.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628026","title":"Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628026?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:13","pubTimestamp":1786061623,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, Inc. (($TARS)) has held its Q2 earnings call. Read on for the main highlights of the call. Tarsus Pharmaceuticals’ latest e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-balances-xdemvy-surge-with-retina-bet?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tarsus-pharmaceuticals-balances-xdemvy-surge-with-retina-bet?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGLO","FEBU","TARS","PMDE","GXDW","VOTE","VGFPF","DECU","BK4007","JOYT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":0.1126},{"period":"3month","weight":0.2513},{"period":"6month","weight":0.2251},{"period":"1year","weight":0.5289},{"period":"ytd","weight":-0.0348}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.002743},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037237},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.051747},{"month":4,"riseRate":0.5,"avgChangeRate":0.00177},{"month":5,"riseRate":0.5,"avgChangeRate":-0.038644},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027034},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.030731},{"month":8,"riseRate":0.833333,"avgChangeRate":0.146034},{"month":9,"riseRate":0.833333,"avgChangeRate":0.038904},{"month":10,"riseRate":0.8,"avgChangeRate":0.135195},{"month":11,"riseRate":0.666667,"avgChangeRate":0.092511},{"month":12,"riseRate":0.666667,"avgChangeRate":0.122111}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}